A. Aziz Ould Ismail
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
A. Aziz Ould Ismail has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Candice C. Black
Department of Pathology and Laboratory Medicine Dartmouth Health Lebanon New Hampshire USA
1 shared publication- Catherine Liu
University of Rochester Medical Center
1 shared publication - Chiamaka L. Okorie
Geisel School of Medicine at Dartmouth, Hanover, USA
1 shared publication - Darcy A. Kerr
Dartmouth-Hitchcock Medical Center
1 shared publication David A. Pastel
Department of Radiology Dartmouth Health Lebanon New Hampshire USA
1 shared publicationElise Gatsby
Affiliation VA Salt Lake City Health Care System and University of Utah, Salt Lake City, UT, United States of America
1 shared publication
Latest Publications
- Open Access
- 17 June 2026
- Published by Elsevier in Academic Pathology
- Vol. 13 (3) , 100275
Evaluating artificial intelligence-generated multiple-choice questions in clinical pathology
- 17 June 2026
- Published by Elsevier in Academic Pathology
- Vol. 13 (3) , 100275
Open AccessEvaluating artificial intelligence-generated multiple-choice questions in clinical pathology
- 23 April 2026
- Published by Wiley in Head & Neck
- Vol. 48 (10) , 2713-2719
The Utility of Comprehensive Sampling in Cervical Lymph Node Dissection for Head and Neck Squamous Cell Carcinoma: Is More Better?
Purpose: To evaluate whether comprehensive sampling of cervical lymphadenectomy tissue increases lymph node yield (LNY) and improves staging adequacy beyond standard grossing practice. Methods: At a single academic center, a comprehensive grossing protocol was introduced in which entire cervical lymphadenectomy specimens (levels I–V) were submitted for histologic evaluation rather than only grossly identified lymph nodes. Ninety‐one cervical lymphadenectomy specimens from 22 HNSCC patients were analyzed. For each case, standard‐protocol LNY was recorded; additional lymph nodes (positive and negative) recovered by the comprehensive protocol were counted, and changes in pathologic stage and adequacy relative to the 18‐node benchmark were assessed. Additional prosection time, tissue block usage, and the correlation between standard and added nodes were also evaluated. Results: The comprehensive protocol increased LNY by a mean of 15.9 ± 12.9 nodes per patient (median 13; 50.1% overall increase), and by 3.8 ± 5.2 nodes per specimen. Only two additional positive nodes (< 0.6%), measuring 1.4 and 4.1 mm, were identified and did not change staging. Two patients with LNY < 18 under the standard protocol exceeded 18 nodes with the comprehensive protocol. Implementation added a mean of 18.5 prosection minutes and 23 extra blocks per case, with poor correlation between standard and added nodes ( r 2 = 0.15). Conclusion: Comprehensive submission markedly increases lymph node counts and can convert some dissections from inadequate to adequate by numeric criteria. However, in this cohort it produced no staging changes and required substantial laboratory resources. These findings support selective rather than universal use of comprehensive sampling in neck dissection evaluation.
- 23 April 2026
- Published by Wiley in Head & Neck
- Vol. 48 (10) , 2713-2719
The Utility of Comprehensive Sampling in Cervical Lymph Node Dissection for Head and Neck Squamous Cell Carcinoma: Is More Better?
Purpose: To evaluate whether comprehensive sampling of cervical lymphadenectomy tissue increases lymph node yield (LNY) and improves staging adequacy beyond standard grossing practice. Methods: At a single academic center, a comprehensive grossing protocol was introduced in which entire cervical lymphadenectomy specimens (levels I–V) were submitted for histologic evaluation rather than only grossly identified lymph nodes. Ninety‐one cervical lymphadenectomy specimens from 22 HNSCC patients were analyzed. For each case, standard‐protocol LNY was recorded; additional lymph nodes (positive and negative) recovered by the comprehensive protocol were counted, and changes in pathologic stage and adequacy relative to the 18‐node benchmark were assessed. Additional prosection time, tissue block usage, and the correlation between standard and added nodes were also evaluated. Results: The comprehensive protocol increased LNY by a mean of 15.9 ± 12.9 nodes per patient (median 13; 50.1% overall increase), and by 3.8 ± 5.2 nodes per specimen. Only two additional positive nodes (< 0.6%), measuring 1.4 and 4.1 mm, were identified and did not change staging. Two patients with LNY < 18 under the standard protocol exceeded 18 nodes with the comprehensive protocol. Implementation added a mean of 18.5 prosection minutes and 23 extra blocks per case, with poor correlation between standard and added nodes ( r 2 = 0.15). Conclusion: Comprehensive submission markedly increases lymph node counts and can convert some dissections from inadequate to adequate by numeric criteria. However, in this cohort it produced no staging changes and required substantial laboratory resources. These findings support selective rather than universal use of comprehensive sampling in neck dissection evaluation.
- Open Access
- 7 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (4) , 2044
Exploring the Molecular Tumor Microenvironment and Translational Biomarkers in Brain Metastases of Non-Small-Cell Lung Cancer
Brain metastases represent a significant clinical challenge in the treatment of non-small-cell lung cancer (NSCLC), often leading to a severe decline in patient prognosis and survival. Recent advances in imaging and systemic treatments have increased the detection rates of brain metastases, yet clinical outcomes remain dismal due to the complexity of the metastatic tumor microenvironment (TME) and the lack of specific biomarkers for early detection and targeted therapy. The intricate interplay between NSCLC tumor cells and the surrounding TME in brain metastases is pivotal, influencing tumor progression, immune evasion, and response to therapy. This underscores the necessity for a deeper understanding of the molecular underpinnings of brain metastases, tumor microenvironment, and the identification of actionable biomarkers that can inform multimodal treatment approaches. The goal of this review is to synthesize current insights into the TME and elucidate molecular mechanisms in NSCLC brain metastases. Furthermore, we will explore the promising horizon of emerging biomarkers, both tissue- and liquid-based, that hold the potential to radically transform the treatment strategies and the enhancement of patient outcomes.
- 7 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (4) , 2044
Open AccessExploring the Molecular Tumor Microenvironment and Translational Biomarkers in Brain Metastases of Non-Small-Cell Lung Cancer
Brain metastases represent a significant clinical challenge in the treatment of non-small-cell lung cancer (NSCLC), often leading to a severe decline in patient prognosis and survival. Recent advances in imaging and systemic treatments have increased the detection rates of brain metastases, yet clinical outcomes remain dismal due to the complexity of the metastatic tumor microenvironment (TME) and the lack of specific biomarkers for early detection and targeted therapy. The intricate interplay between NSCLC tumor cells and the surrounding TME in brain metastases is pivotal, influencing tumor progression, immune evasion, and response to therapy. This underscores the necessity for a deeper understanding of the molecular underpinnings of brain metastases, tumor microenvironment, and the identification of actionable biomarkers that can inform multimodal treatment approaches. The goal of this review is to synthesize current insights into the TME and elucidate molecular mechanisms in NSCLC brain metastases. Furthermore, we will explore the promising horizon of emerging biomarkers, both tissue- and liquid-based, that hold the potential to radically transform the treatment strategies and the enhancement of patient outcomes.
- Open Access
- 13 May 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (5) , e0267915
Using electronic health records to streamline provider recruitment for implementation science studies
Background: Healthcare providers are often targeted as research participants, especially for implementation science studies evaluating provider- or system-level issues. Frequently, provider eligibility is based on both provider and patient factors. Manual chart review and self-report are common provider screening strategies but require substantial time, effort, and resources. The automated use of electronic health record (EHR) data may streamline provider identification for implementation science research. Here, we describe an approach to provider screening for a Veterans Health Administration (VHA)-funded study focused on implementing risk-aligned surveillance for bladder cancer patients. Methods: Our goal was to identify providers at 6 pre-specified facilities who performed ≥10 surveillance cystoscopy procedures among bladder cancer patients in the 12 months prior to recruitment start on January 16, 2020, and who were currently practicing at 1 of 6 pre-specified facilities. Using VHA EHR data (using CPT, ICD10 procedure, and ICD10 diagnosis codes), we identified cystoscopy procedures performed after an initial bladder cancer diagnosis (i.e., surveillance procedures). Procedures were linked to VHA staff data to determine the provider of record, the number of cystoscopies they performed, and their current location of practice. To validate this approach, we performed a chart review of 105 procedures performed by a random sample of identified providers. The proportion of correctly identified procedures was calculated (Positive Predictive Value (PPV)), along with binomial 95% confidence intervals (CI). Findings: We identified 1,917,856 cystoscopies performed on 703,324 patients from October 1, 1999—January 16, 2020, across the nationwide VHA. Of those procedures, 40% were done on patients who had a prior record of bladder cancer and were completed by 15,065 distinct providers. Of those, 61 performed ≥ 10 procedures and were currently practicing at 1 of the 6 facilities of interest in the 1 year prior to study recruitment. The random chart review of 7 providers found 101 of 105 procedures (PPV: 96%; 95% CI: 91% to 99%) were surveillance procedures and were performed by the selected provider on the recorded date. Implications: These results show that EHR data can be used for accurate identification of healthcare providers as research participants when inclusion criteria consist of both patient- (temporal relationship between diagnosis and procedure) and provider-level (frequency of procedure and location of current practice) factors. As administrative codes and provider identifiers are collected in most, if not all, EHRs for billing purposes this approach can be translated from provider recruitment in VHA to other healthcare systems. Implementation studies should consider this method of screening providers.
- 13 May 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (5) , e0267915
Open AccessUsing electronic health records to streamline provider recruitment for implementation science studies
Background: Healthcare providers are often targeted as research participants, especially for implementation science studies evaluating provider- or system-level issues. Frequently, provider eligibility is based on both provider and patient factors. Manual chart review and self-report are common provider screening strategies but require substantial time, effort, and resources. The automated use of electronic health record (EHR) data may streamline provider identification for implementation science research. Here, we describe an approach to provider screening for a Veterans Health Administration (VHA)-funded study focused on implementing risk-aligned surveillance for bladder cancer patients. Methods: Our goal was to identify providers at 6 pre-specified facilities who performed ≥10 surveillance cystoscopy procedures among bladder cancer patients in the 12 months prior to recruitment start on January 16, 2020, and who were currently practicing at 1 of 6 pre-specified facilities. Using VHA EHR data (using CPT, ICD10 procedure, and ICD10 diagnosis codes), we identified cystoscopy procedures performed after an initial bladder cancer diagnosis (i.e., surveillance procedures). Procedures were linked to VHA staff data to determine the provider of record, the number of cystoscopies they performed, and their current location of practice. To validate this approach, we performed a chart review of 105 procedures performed by a random sample of identified providers. The proportion of correctly identified procedures was calculated (Positive Predictive Value (PPV)), along with binomial 95% confidence intervals (CI). Findings: We identified 1,917,856 cystoscopies performed on 703,324 patients from October 1, 1999—January 16, 2020, across the nationwide VHA. Of those procedures, 40% were done on patients who had a prior record of bladder cancer and were completed by 15,065 distinct providers. Of those, 61 performed ≥ 10 procedures and were currently practicing at 1 of the 6 facilities of interest in the 1 year prior to study recruitment. The random chart review of 7 providers found 101 of 105 procedures (PPV: 96%; 95% CI: 91% to 99%) were surveillance procedures and were performed by the selected provider on the recorded date. Implications: These results show that EHR data can be used for accurate identification of healthcare providers as research participants when inclusion criteria consist of both patient- (temporal relationship between diagnosis and procedure) and provider-level (frequency of procedure and location of current practice) factors. As administrative codes and provider identifiers are collected in most, if not all, EHRs for billing purposes this approach can be translated from provider recruitment in VHA to other healthcare systems. Implementation studies should consider this method of screening providers.